Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Sorafenib in advanced hepatocellular carcinoma.
BACKGROUND
No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular… Expand
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.
BACKGROUND & AIMS
Patients with cirrhosis hospitalized for an acute decompensation (AD) and organ failure are at risk for imminent death and considered to have acute-on-chronic liver failure (ACLF).… Expand
Telaprevir for previously untreated chronic hepatitis C virus infection.
- I. Jacobson, J. McHutchison, +20 authors S. Zeuzem
- Medicine
- The New England journal of medicine
- 22 June 2011
BACKGROUND
In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has… Expand
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
- Tara L. Kieffer, Doug J. Bartels, +10 authors A. Kwong
- 2009
- 1,608
- 94
- PDF
Telaprevir for retreatment of HCV infection.
- S. Zeuzem, P. Andreone, +22 authors M. Beumont
- Medicine
- The New England journal of medicine
- 22 June 2011
BACKGROUND
Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin.
METHODS
In this… Expand
Boceprevir for previously treated chronic HCV genotype 1 infection.
- B. Bacon, S. Gordon, +11 authors R. Esteban
- Medicine
- The New England journal of medicine
- 30 March 2011
BACKGROUND
In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are… Expand
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
- C. Hézode, N. Forestier, +15 authors S. Zeuzem
- Medicine
- The New England journal of medicine
- 10 December 2009
BACKGROUND
In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of… Expand
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
- H. Janssen, M. Zonneveld, H. Senturk, S. Zeuzem, for the Hbv 99-01 Study Group
- Medicine
- The Lancet
- 8 January 2005
BACKGROUND
Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might… Expand
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
- S. Zeuzem, G. Dusheiko, +14 authors R. Esteban
- Medicine
- The New England journal of medicine
- 21 May 2014
BACKGROUND
In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients… Expand
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
- F. Poordad, C. Hézode, +14 authors B. Bernstein
- Medicine
- The New England journal of medicine
- 21 May 2014
BACKGROUND
Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the… Expand